The development of the polysomal RNA vaccine to the ovarian cancer

2010 Fiscal Year Final Research Report

• Project/Area Number: 19791178
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Obstetrics and gynecology
• Research Institution: Kurume University
• Principal Investigator: TSUDA Naotake Kurume University, 医学部, 助教 (60341351)
• Project Period (FY): 2007 – 2010
• Keywords: RNA / 癌ワクチン

Research Abstract

The purpose of this research is to develop the new cancer vaccine with polysomal RNA(the complex of RNA and peptide). Furthermore, we would like to show the induction of the CTL and Natural Killer Cell by polysomal RNA which is pre-treated with the low dose paclitaxel.

Research Products

• [Journal Article] N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. (2009)
  • Author(s): Matsueda S, Gao H, Efferson CL, Tsuda N, Ishiyama S, Li Y, Ioannides MG, Fisk B, Peoples GE, Ioannides CG
  • Journal Title: Anticancer Research 29(7) Pages: 2427-2435
  • Peer Reviewed
• [Journal Article] Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines (2009)
  • Author(s): Li Y, Matsueda S, Efferson CL, Tsuda N, Kawano K, Gao H, Peoples GE, Ioannides CG.
  • Journal Title: Anticancer Research 29(1) Pages: 41-58
  • Peer Reviewed
• [Journal Article] Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. (2009)
  • Author(s): Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M, Kakuma T, Kage M, Hori D, Kamura T.
  • Journal Title: Br J Cancer. 101(6) Pages: 967-972
  • Peer Reviewed
• [Journal Article] Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines. (2009)
  • Author(s): Li Y, Matsueda S, Efferson CL, Tsuda N, Kawano K, Gao H, Peoples GE, Ioannides CG.
  • Journal Title: Anticancer Res. 29(1) Pages: 41-58
  • Peer Reviewed
• [Journal Article] Synthetic microRNA targeting glioma-associated antigen-1 protein. (2009)
  • Author(s): Tsuda N, Mine T, Ioannides CG, Chang DZ.
  • Journal Title: Methods Mol Biol. 487 Pages: 435-449
  • Peer Reviewed
• [Journal Article] Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. (2008)
  • Author(s): Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T.
  • Journal Title: Cancer Lett. 264(1) Pages: 36-43
  • Peer Reviewed
• [Journal Article] HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells : The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor (2008)
  • Author(s): Li Y, Ishiyama S, Matsueda S, Tsuda N, Ioannides CG
  • Journal Title: Oncol Rep 19(6) Pages: 1445-1452
  • Peer Reviewed
• [Remarks] ホームページ等